Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554893 | 1.00 | SRD5A2 (0.44) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL3553726 | 0.92 | SRD5A2 (0.41) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL3553728 | 0.92 | SRD5A2 (0.41) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL3550385 | 0.71 | SRD5A2 (0.51) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL3550383 | 0.71 | SRD5A2 (0.51) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL2846425 | 0.70 | SRD5A2 (0.50) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL2846423 | 0.70 | SRD5A2 (0.50) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL9590622 | 0.70 | MEN1 (0.55) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL3552163 | 0.67 | SRD5A2 (0.47) | SRD5A2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL3552164 | 0.67 | SRD5A2 (0.47) | SRD5A2MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674821-B2 | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-7462631-B2 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| EP-1833812-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL]AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-09-19 | — | — | EP | disclosed |
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-11-23 | — | — | US | disclosed |
| EP-1678159-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006070106-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005035488-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF AS CANNABINOID CB-1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | CNR1, CNR2, TPMT | SRD5A2 2053/4885MEN1 1947/4885KMT2A 1597/4885 |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR1, CNR2, UTS2R | SRD5A2 2122/4885MEN1 3821/4885KMT2A 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.